References
- Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.
- Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol. 2010;5(2):260–74.
- D'Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–36.
- d'Amato TA, Landreneau RJ, Ricketts W, Huang W, Parker R, Mechetner E, et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007;133(2):352–63.
- Cetintas VB, Tetik A, Cok G, Kucukaslan AS, Kosova B, Gunduz C, et al. Role of 14-3-3σ in resistance to cisplatin in non-small cell lung cancer cells. Cell Biol Int. 2013;37(1):78–86.
- Ueda K, Kawashima H, Ohtani S, Deng WG, Ravoori M, Bankson J, et al. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006;66(19):9682–90.
- Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003;94(4):394–9.
- Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y. MiRNA-21: a biomarker predictive for platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Cancer Biol Ther. 2012;13(5):330–40.
- Liu H, Zhang T, Li X, Huang J, Wu B, Huang X, et al. Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci. 2008;99(11):2185–92.
- Kumar S, Guleria R, Singh V, Bharti AC, Mohan A, Das BC. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer. 2010;70(2):211–7.
- Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(18 Pt 1):5981–7.
- Lamanna AC, Karbstein K. Nob1 binds the single-stranded cleavage site D at the 30-end of 18S rRNA with its PIN domain. Proc Natl Acad Sci USA. 2009;106:14259–64.
- Hong L, Chen Z, Zhang X, Xia L, Han Z, Lu Y, et al. Zinc ribbon domain containing 1 protein: modulator of multidrug resistance, tumorigenesis and cell cycle. Exp Oncol. 2006;28(4):258–62.
- Liu K, Gu MM, Chen HL, You QS. NOB1 in non-small-cell lung cancer: expression profile and clinical significance. Pathol Oncol Res. 2014;20(2):461–6.
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
- Tone Y, Tanahashi N, Tanaka K, Fujimuro M, Yokosawa H, Toh-e A. Nob1p, a new essential protein, associates with the 26S proteasome of growing Saccharomyces cerevisiae cells. Gene. 2000;243(1–2):37–45.
- Tone Y, Toh-E A. Nob1p is required for biogenesis of the 26S proteasome and degraded upon its maturation in Saccharomyces cerevisiae. Genes Dev. 2002;16(24):3142–57.
- Veith T, Martin R, Wurm JP, Weis BL, Duchardt-Ferner E, Safferthal C, et al. Structural and functional analysis of the archaeal endonuclease Nob1. Nucleic Acids Res. 2012;40(7):3259–74.
- Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thorac Oncol. 2007;2(8):735–40.
- Liu H, Wu Y, Wang Z, Song Y. Response to first-line chemotherapy of docetaxel combined with platinum predicting the prognosis and subsequent treatment of patients with non-small cell lung cancer. Thorac Cancer. 2014;5(4):337–42.